Zacks: Brokerages Anticipate BioCardia, Inc. (NASDAQ:BCDA) to Post -$0.28 Earnings Per Share
Equities research analysts predict that BioCardia, Inc. (NASDAQ:BCDA) will announce earnings of ($0.28) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for BioCardia’s earnings. The lowest EPS estimate is ($0.29) and the highest is ($0.26). BioCardia reported earnings per share of ($0.55) in the same quarter last year, which suggests a positive year-over-year growth rate of 49.1%. The business is expected to announce its next quarterly earnings report on Tuesday, November 17th.
On average, analysts expect that BioCardia will report full year earnings of ($1.40) per share for the current year, with EPS estimates ranging from ($1.55) to ($1.25). For the next financial year, analysts anticipate that the firm will post earnings of ($0.72) per share, with EPS estimates ranging from ($1.09) to ($0.35). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for BioCardia.
BCDA opened at $2.38 on Wednesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.66 and a current ratio of 2.66. The stock has a market cap of $29.51 million, a PE ratio of -1.05 and a beta of 1.76. BioCardia has a one year low of $2.01 and a one year high of $7.25.
BioCardia, Inc, a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure.
Recommended Story: History of the Euro STOXX 50 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.